Clinical Trial Update: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of RO4929097, a gamma-secretase inhibitor, with Cediranib maleate in adults with advanced solid tumors. The study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Ependymoma
• Breast Cancer
• Colon Cancer
• Glioblastoma
• Gliosarcoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Cediranib (Cediranib)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Status: COMPLETED